NCT03984110已完成4 期
The Use of a Combination of Ozurdex and Eylea Versus Eylea Monotherapy for Diabetic Macular Edema: A Prospective, Comparative Trial
适应症
干预措施
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Central Subfield Thickness (CST)
研究概览
简要总结
One Year Trial Evaluating Safety of Ozurdex With Eylea (COED)
详细描述
In this study, the investigators aim to compare the effects of combined use of intravitreal injections of Ozurdex every three3 months and monthly Eylea/aflibercept to monthly intravitreal injections of aflibercept alone as measured by improvement in central subfield thickness from baseline at Week 48 in eyes with center-involving Diabetic Macular Edema and best-corrected visual acuity of 20/40 or worse
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Type 1 or 2 diabetic patients
- •At least 18 years of age, understands the language of the informed consent, and is willing and able to provide written informed consent before any study procedures
- •Pseudophakic or phakic lens status with intact posterior lens capsule and/or Nd: Yttrium Aluminum Garnet (YAG) laser capsulotomy that in the investigator's opinion is not likely to permit dislocation of Ozurdex implant into the anterior chamber
- •Center-involving DME > 300 µm
- •Baseline BCVA between 20/40 - 20/320
- •Eyes with intraocular pressure (IOP) ≤ 21 and / or treatment with < 2 topical IOP-lowering medications (eyes with history of previous angle -closure or similar conditions that have been successfully treated with either laser or surgical intervention are allowed as long as the visual fields and optic nerves have been stable for > 1 year prior to study entry and the patient has been and can be safely dilated)
排除标准
- •Patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases.
- •Patients with known hypersensitivity to any components of Eylea or Ozurdex
- •Patient has suffered from a stroke or transient ischemic attack (TIA) in the last 6 months
- •Patients using topical anti-inflammatory medication for the duration of the study
- •Patients with Anterior Chamber Intraocular Lens (ACIOL) and rupture of the posterior lens capsule
- •Prior panretinal photocoagulation or macular laser treatments within 90 days of screening
- •Previous vitrectomy
- •Any ocular condition that in the opinion of the investigator would not permit improvement of visual acuity with resolution of DME (e.g., foveal atrophy, pigment abnormalities, dense subfoveal hard exudates and/or poor foveal architecture suggestive of photoreceptor loss)
- •Patients with retinal diseases other than diabetes that can affect macular edema
- •Eyes with a history of advanced glaucoma (optic nerve head change consistent with glaucoma damage and/or glaucomatous visual field loss), uncontrolled ocular hypertension (baseline IOP > 21 mmHg despite use of ≥ 2 topical IOP-lowering medication)
- •Eyes with a history of steroid response (i.e., increase of ≥ 5 mmHg IOP following topical steroid treatment)
- •Female patients who are pregnant or breastfeeding
- •Patients who are unable to attend scheduled follow-up visits throughout the 24-week study
- •Any intravitreal anti-Vascular Endothelial Growth Factor (VEGF) treatment to study eye within 3 months prior to Day 1
- •Use of systemic steroid, anti-VEGF or pro-VEGF treatment within 4 months prior to enrollment or anticipated use during the study (these drugs are prohibited from use during the study)
- •History of any previous treatment in the study eye with an ocular corticosteroid implant (eg Iluvien, Ozurdex, Retisert)
- •Has scarring from laser photocoagulation in the study eye that would compromise Visual Acuity (VA); or scarring or abnormality from other macular condition, in the investigator's medical judgement, would limit VA (such as an epiretinal membrane or macular hole)
- •Has significant media opacity precluding evaluation of retina and vitreous in the study eye. This includes cataract that is felt to be a major contributor to reduced visual acuity and/or likely to undergo surgical repair within 3 months of randomization.
- •Has any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study (eg, infection, uncontrolled elevated blood pressure, cardiovascular disease, poor glycemic control) or put the subject at risk due to study treatment or procedures
- •Has had a myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 1 month before enrollment
研究组 & 干预措施
Combination of Ozurdex and Eylea
Experimental
Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
干预措施: Ozurdex (Drug)
Combination of Ozurdex and Eylea
Experimental
Eyes receiving intravitreal injection of Ozurdex every 3 months (as needed per protocol) and intravitreal injection of Eylea every month (as needed per protocol)
干预措施: Eylea (Drug)
Eylea Monotherapy
Active Comparator
Eyes receiving intravitreal injection of Eylea every month (as needed per protocol)
干预措施: Eylea (Drug)
结局指标
主要结局
Central Subfield Thickness (CST)
时间窗: 48 weeks
Change in Central Subfield Thickness (CST) on Spectral Domain-Optical Coherence Tomography (SD-OCT)
次要结局
- CST(12 weeks, 24 weeks, and 36 weeks)
- Best Corrected Visual Acuity (BCVA)(12 weeks, 24 weeks, 36 weeks, and 48 weeks)
- Number of additional Intravitreal Therapy (IVT) aflibercept injections required over 48 weeks(48 weeks)
- Monthly mean changes from baseline in CST(48 weeks)
- Monthly mean changes from baseline in BCVA(48 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular EdemaDiabetic Macular EdemaNCT03629210Pradeepa Yoganathan
已完成
不适用
Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.Diabetic Macular EdemaNCT02121197Association for Innovation and Biomedical Research on Light and Image321
终止
4 期
Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular EdemaDiabetic Macular EdemaNCT02684084North Toronto Eye Care Laser and Eye Specialists5
已完成
不适用
A Long-Term Safety Study of OZURDEX® in Clinical PracticeMacular EdemaUveitis, PosteriorRetinal Vein OcclusionNCT01539577Allergan875
已完成
4 期
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein OcclusionMacular EdemaRetinal Vein OcclusionNCT01427751Allergan307